| abstract |
[Chemical 1] The present invention relates to a novel substituted heterocyclic ring having binding affinity for serotonin receptors, particularly 5-HT2A and 5-HT2C receptors, and dopamine receptors, particularly dopamine D2 receptors, and having norepinephrine reabsorption-reducing properties. Tetracyclic tetrahydrofuran derivatives, pharmaceutical compositions comprising the compounds according to the invention, in particular the prevention of a range of psychiatric and neurological disorders, in particular certain psychoses, cardiovascular and gastric motility disorders and / or Or its use as a medicament for treatment, as well as methods for their production. The compounds according to the invention can be represented by the general formula (I) and also their pharmaceutically acceptable acid or base addition salts, their stereochemically isomeric forms, their N-oxide forms And their prodrugs, where all substituents are defined as in claim 1. |